These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37537670)

  • 1. How to START? Four pillars to optimally begin your orphan drug development.
    Jonker AH; Batista L; Gabaldo M; Hivert V; Ardigo D;
    Orphanet J Rare Dis; 2023 Aug; 18(1):229. PubMed ID: 37537670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orphan Medicines for Pediatric Use: A Focus on the European Union.
    Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
    Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.
    Tambuyzer E; Vandendriessche B; Austin CP; Brooks PJ; Larsson K; Miller Needleman KI; Valentine J; Davies K; Groft SC; Preti R; Oprea TI; Prunotto M
    Nat Rev Drug Discov; 2020 Feb; 19(2):93-111. PubMed ID: 31836861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
    Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
    Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
    Micallef J; Blin O
    Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orphan drug clinical development.
    Blin O; Lefebvre MN; Rascol O; Micallef J
    Therapie; 2020 Apr; 75(2):141-147. PubMed ID: 32247678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases.
    Duarte DM; Beatriz da Silva Lima M; Sepodes B
    Regul Toxicol Pharmacol; 2020 Dec; 118():104810. PubMed ID: 33122047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases.
    Lanar S; Acquadro C; Seaton J; Savre I; Arnould B
    Orphanet J Rare Dis; 2020 Jun; 15(1):134. PubMed ID: 32493385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington's Disease.
    Mullin AP; Corey D; Turner EC; Liwski R; Olson D; Burton J; Sivakumaran S; Hudson LD; Romero K; Stephenson DT; Larkindale J
    Clin Transl Sci; 2021 Jan; 14(1):214-221. PubMed ID: 32702147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Potential Challenges for Developing Generic Orphan Drugs for Rare Diseases: A Survey of US and European Markets.
    Murthannagari VR; Gonna Nandhi Krishnan G; Manu KV; Jayachandraiah CT; Mandadhi Rajendra PK; Ahmed SS
    Value Health Reg Issues; 2023 May; 35():87-94. PubMed ID: 36921379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.
    Di Paolo A; Arrigoni E
    Drugs; 2018 Mar; 78(4):399-410. PubMed ID: 29464665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.
    Miller KL; Mueller C; Liu G; Miller Needleman KI; Maynard J
    Orphanet J Rare Dis; 2020 Sep; 15(1):234. PubMed ID: 32883327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and trend of clinical development of orphan drugs in China.
    Xiang Z; Jiang W; Yan B; Jiang J; Zheng H
    Orphanet J Rare Dis; 2022 Jul; 17(1):294. PubMed ID: 35897012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
    Tambuyzer E
    Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research advances in pharmacotherapy for rare diseases in children].
    Li JQ; Wang HJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jul; 25(7):759-766. PubMed ID: 37529960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Social Media in Orphan Drug Development.
    Milne CP; Ni W
    Clin Ther; 2017 Nov; 39(11):2173-2180. PubMed ID: 28942336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.
    Micallef J; Boutouyrie P; Blin O
    Fundam Clin Pharmacol; 2017 Dec; 31(6):685-694. PubMed ID: 28779530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.